Form D · Biotechnology
TendoNova Corp
Atlanta, GA · CIK 0001774275
Offering snapshot reported Aug 29, 2024 · SEC filing
- Reported sold
- $270K Offering amount: $400K
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 26, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 29, 2024 | Initial | $270,000 | No comparison | 3 | SEC filing |
| May 29, 2024 | Amendment | $761,999 | $135,000vs Mar 19, 2024 | 6 | SEC filing |
| Mar 19, 2024 | Amendment | $626,999 | $25,000vs Mar 1, 2024 | 5 | SEC filing |
| Mar 1, 2024 | Initial | $601,999 | No comparison | 4 | SEC filing |
| Jan 9, 2024 | Initial | $250,000 | No comparison | 10 | SEC filing |
| Oct 10, 2023 | Amendment | $300,000 | $75,000vs Aug 28, 2023 | 3 | SEC filing |
| Aug 28, 2023 | Initial | $225,000 | No comparison | 2 | SEC filing |
| Dec 27, 2022 | Amendment | $440,000 | $225,000vs Nov 4, 2022 | 8 | SEC filing |
| Nov 4, 2022 | Amendment | $215,000 | $55,000vs Aug 12, 2022 | 6 | SEC filing |
| Aug 22, 2022 | Amendment | $446,300 | $146,300vs Mar 30, 2022 | 11 | SEC filing |
| Aug 12, 2022 | Initial | $160,000 | No comparison | 4 | SEC filing |
| Mar 30, 2022 | Amendment | $300,000 | $130,000vs Oct 7, 2021 | 9 | SEC filing |
| Oct 7, 2021 | Initial | $170,000 | No comparison | 3 | SEC filing |
| Feb 2, 2021 | Amendment | $1,379,300 | $50,000vs Dec 7, 2020 | 13 | SEC filing |
| Dec 7, 2020 | Amendment | $1,329,300 | $269,300vs Jun 17, 2020 | 11 | SEC filing |
| Jun 17, 2020 | Amendment | $1,060,000 | $200,000vs Jun 11, 2020 | 7 | SEC filing |
| Jun 11, 2020 | Amendment | $860,000 | $25,000vs May 26, 2020 | 6 | SEC filing |
| May 26, 2020 | Amendment | $835,000 | $500,000vs Feb 28, 2020 | 5 | SEC filing |
| Feb 28, 2020 | Amendment | $335,000 | $10,000vs Feb 21, 2020 | 4 | SEC filing |
| Feb 21, 2020 | Amendment | $325,000 | $125,000vs Apr 18, 2019 | 3 | SEC filing |
| Apr 18, 2019 | Initial | $200,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-522808
Source: Form D, filed Aug 29, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ian Campbell | Director, Executive |
| Jeff Clark | Director |
| Luka Grujic | Director |
| Peter Haaland | Director |
| Shawna Khouri | Director |
| Louis Malice | Director |
| Brett Rogers | Director |
| Mark Samuels | Director, Executive |
| Jonathan Shaw | Director |
| Roy Wallen | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
75 Fifth Street Nw, Suite 2106
Atlanta, GA, 30308
Atlanta, GA, 30308